Clinical Implications of Eosinopenia in Adult Brucellosis Patients

¹ Department of Infection Disease, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China; Department of Infection Disease, The Fifth People’s Hospital of Suzhou, Suzhou 215000, Jiangsu Province, China,

JCNR 2024 , 8(11), 266–276; https://doi.org/10.26689/jcnr.v8i11.8664

© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Objective: To analyze the differences between eosinopenia and non-eosinopenia brucellosis patients in depth. Methods: Medical records of brucellosis patients admitted to the Affiliated Infectious Diseases Hospital of Soochow University between January 1, 2013, and December 31, 2023, were reviewed retrospectively. Patients were categorized into an eosinopenia group and a non-eosinopenia group based on pre-treatment eosinophil levels. A nonparametric test was performed to estimate the differences between the two groups. Results: Among the 125 patients, 66 (52.80%) experienced eosinopenia. Patients with eosinopenia were older (52.09 ± 15.63 years vs. 46.08 ± 16.39 years, P = 0.024), had a higher proportion of hypertension (21.21% vs. 6.78%, P = 0.024), and exhibited a greater likelihood of complications (75.76% vs. 35.59%, P = 0.000), particularly hematological (68.18% vs. 23.73%, P = 0.000) and relapse (19.70% vs. 6.78%, P = 0.040). The eosinopenia group also showed higher levels of ALT (29.00 vs. 20.00, P = 0.003), AST (29.00 vs. 22.00, P = 0.037), and LOS (17.50 vs. 12.00, P = 0.000). Among certain inflammatory indicators related to brucellosis, the eosinopenia group demonstrated lower levels, such as MPV (9.75 vs. 10.70, P = 0.000), MLR (0.28 vs. 0.36, P = 0.002), and SIRI (0.67 vs. 1.03, P = 0.004). Conclusion: Brucellosis patients with eosinopenia differed in clinical manifestations and prognosis. Monitoring eosinophils may provide better prognostic assessment and suggest potential new treatment options.

References

Liu Z, Gao L, Wang M, et al., 2024, Long Ignored But Making A Comeback: A Worldwide Epidemiological Evolution of Human Brucellosis. Emerg Microbes Infect, 13(1): 2290839. https://doi.org/10.1080/22221751.2023.2290839

National Health Commission of the People’s Republic of China, 2023, China Health Statistical Yearbook (2022). China Union Medical College Press, Beijing.

Jin M, Fan Z, Gao R, et al., 2023, Research Progress on Complications of Brucellosis. Front Cell Infect Microbiol, 13: 1136674. https://doi.org/10.3389/fcimb.2023.1136674

Kaya S, Elaldi N, Deveci O, et al., 2018, Cytopenia in Adult Brucellosis Patients. Indian J Med Res, 147(1): 73–80. https://doi.org/10.4103/ijmr.IJMR_542_15

Wang JN, Li BJ, Yuan J, et al., 2023, Brucellosis Complicated by Myelofibrosis: Report of Five Cases and Review of Literature. Int J Clin Exp Pathol, 16(7): 164–171.

Guo M, Zhang L, Chen K, et al., 2024, Hemophagocytic Lymphohistiocytosis Associated with Brucellosis. Diagn Microbiol Infect Dis, 109(3): 116289. https://doi.org/10.1016/j.diagmicrobio.2024.116289

Çelik M, Arslan Y, Topcu E, et al., 2024, Investigation of Hematologic Findings Related to Brucellosis in Anatolian Region. Saudi Med J, 45(5): 495–501. https://doi.org/10.15537/smj.2024.45.5.20230847

Samarasinghe AE, Melo RC, Duan S, et al., 2017, Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus. J Immunol, 198(8): 3214–3226. https://doi.org/10.4049/jimmunol.1600787

Rosenberg HF, Foster PS, 2021, Eosinophils and COVID-19: Diagnosis, Prognosis, and Vaccination Strategies. Semin Immunopathol, 43(3): 383–392. https://doi.org/10.1007/s00281-021-00850-3

Yang L, Zhang W, Shen X, et al., 2022, Predictive Role of Blood Eosinophils in Adult Varicella Patients. Epidemiol Infect, 150: e127. doi:10.1017/S095026882200111X

Jiao PF, Chu WL, Ren GF, et al., 2015, Expression of Eosinophils Be Beneficial to Early Clinical Diagnosis of Brucellosis. Int J Clin Exp Med, 8(10): 19491–19495.

Guo MY, Xu K, Cao Y, et al., 2021, Clinical Analysis of Brucellosis in 49 Cases in North Anhui Area. Journal of Tropical Diseases and Parasitology, 19(4): 219.

Gnanaraj J, Parnes A, Francis CW, et al., 2018, Approach to Pancytopenia: Diagnostic Algorithm for Clinical Hematologists. Blood Rev, 32(5): 361–367. https://doi.org/10.1016/j.blre.2018.03.001

Deniz S, Baykam N, Celikbas A, et al., 2015, Screening Household Members of Acute Brucellosis Cases in Endemic Areas and Risk Factors for Brucellosis. Vector Borne Zoonotic Dis, 15(8): 468–472. https://doi.org/10.1089/vbz.2014.1723

Nematollahi S, Ayubi E, Karami M, et al., 2017, Epidemiological Characteristics of Human Brucellosis in Hamadan Province During 2009–2015: Results from the National Notifiable Diseases Surveillance System. Int J Infect Dis, 61: 56–61. https://doi.org/10.1016/j.ijid.2017.06.002

Sayin Kutlu S, Kutlu M, Tuzun T, et al., 2018, Spondylodiscitis: A Common Complication of Brucellosis. J Infect Dev Ctries, 12(7): 550–556. https://doi.org/10.3855/jidc.10557

Demirdal T, Sen P, 2020, Risk Factors for Focal Involvement in Brucellosis. Diagn Microbiol Infect Dis, 97(1): 115003. https://doi.org/10.1016/j.diagmicrobio.2020.115003

Cisneros B, García-Aguirre I, Unzueta J, et al., 2022, Immune System Modulation in Aging: Molecular Mechanisms and Therapeutic Targets. Front Immunol, 13: 1059173. https://doi.org/10.3389/fimmu.2022.1059173

Liu Z, Liang Q, Ren Y, et al., 2023, Immunosenescence: Molecular Mechanisms and Diseases. Signal Transduct Target Ther, 8(1): 200. https://doi.org/10.1038/s41392-023-01451-2

Aoki A, Hirahara K, Kiuchi M, et al., 2021, Eosinophils: Cells Known for Over 140 Years with Broad and New Functions. Allergol Int, 70(1): 3–8. https://doi.org/10.1016/j.alit.2020.09.002

Cift A, Yucel MO, 2018, Comparison of Inflammatory Markers Between Brucella and Non-Brucella Epididymo-Orchitis. Int Braz J Urol, 44(4): 771–778. https://doi.org/10.1590/s1677-5538.ibju.2018.0004.0

Sen P, Demirdal T, Nemli SA, 2019, Predictive Value of Inflammation Markers in Brucellosis. Arch Iran Med, 22(11): 640–645.

Aydin E, Karadag MA, Cecen K, et al., 2016, Association of Mean Platelet Volume and the Monocyte/Lymphocyte Ratio with Brucella-Caused Epididymo-Orchitis. Southeast Asian J Trop Med Public Health, 47(3): 450–456.

Balın ŞÖ, Tartar AS, Akbulut A, 2018, The Predictive Role of Haematological Parameters in the Diagnosis of Osteoarticular Brucellosis. Afr Health Sci, 18(4): 988–994. https://doi.org/10.4314/ahs.v18i4.19

Islam MM, Satici MO, Eroglu SE, 2024, Unraveling the Clinical Significance and Prognostic Value of the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Systemic Immune-Inflammation Index, Systemic Inflammation Response Index, and Delta Neutrophil Index: An Extensive Literature Review. Turk J Emerg Med, 24(1): 8–19. https://doi.org/10.4103/tjem.tjem_198_23

Zhang J, Zhao Q, Liu S, et al., 2024, Clinical Predictive Value of the CRP-Albumin-Lymphocyte Index for Prognosis of Critically Ill Patients with Sepsis in Intensive Care Unit: A Retrospective Single-Center Observational Study. Front Public Health, 12: 1395134. https://doi.org/10.3389/fpubh.2024.1395134

Şah V, Baran Aİ, 2024, Can Hematological Inflammatory Indices Be Used to Differentiate Modic Type 1 Changes from Brucella Spondylodiscitis? Medicina (Kaunas), 60(7): 1131. https://doi.org/10.3390/medicina60071131

Previous article in this issue

Next article in this issue